Download PDF
Arthritis und Rheuma 2017; 37(02): 126-135
DOI: 10.1055/s-0037-1618417
Kinderrheumatologie/Übersichtsarbeit
Schattauer GmbH

Die polyartikuläre Verlaufsform der juvenilen idiopathischen Arthritis

Polyarticular course of JIA
F. Weller-Heinemann
1   Prof.-Hess-Kinderklinik, Zentrum für Kinderheilkunde und Jugendmedizin am Klinikum Bremen – Mitte, Gesundheit Nord Klinikverbund Bremen, Bremen
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

  PDF Download  Permissions and Reprints

Zusammenfassung

Die juvenile Polyarthritis ist mit ca. 20 % die zweithäufigste Verlaufsform der juvenilen idiopathischen Arthritis (JIA). Die Polyarthritis ist aber Ursache eines bedeutenden Teils der Krankheitslast und der Langzeitprobleme der JIA. Etablierte Therapieformen mit Steroiden und konventionellen „disease-modifying antirheumatic drugs” (DMARDs) sind in den vergangenen Jahren insbesondere durch die Zulassung neuer Biologika erheblich erweitert worden. Die Erkrankung, ihre Diagnostik und aktuellen Therapiemöglichkeiten werden dargestellt.

Summary

Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease in infancy and childhood. Approximately 20 % of patients suffer from the polyarticular form of the disease, which causes a substantial disease burden and long-term sequelae. Therapeutic approaches have used steroids and conventional disease-modifying antirheumatic drugs (DMARD), but over the last decade new drugs have become available for the treatment of JIA, in particular biologic DMARD. This article summarizes the clinical characteristics and outcomes, diagnosis and current treatment options of polyarticular JIA.

Schlüsselwörter

Juvenile Polyarthritis - Diagnostik - Therapie - Prognose

Keywords

Polyarticular juvenile arthritis - diagnosis - treatment - prognosis
 

  • Literatur

  • 1 Petty RE. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31 (02) 390-392.
    Google Scholar
  • 2 Modesto C, Antón J, Rodriguez B. et al. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol 2010; 39: 472-479.
    CrossrefPubMedGoogle Scholar
  • 3 Adib N. et al. Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 2008; 47 (07) 991-995.
    CrossrefPubMedGoogle Scholar
  • 4 Abdwani R, Abdalla E, Al AS. et al. Epidemiology of juvenile idiopathic arthritis in Oman. Pediatr Rheumatol Online J 2015; 13: 33
    CrossrefPubMedGoogle Scholar
  • 5 Prakken B. et al. Juvenile idiopathic arthritis. Lancet 2011; 377: 2138-2149.
    CrossrefPubMedGoogle Scholar
  • 6 Greenwald AG. et al. Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group?. Clin Exp Rheumatol 2013; 31 (04) 645-652.
    PubMedGoogle Scholar
  • 7 Saurenmann RK. et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 2007; 56 (06) 1974-1984.
    CrossrefPubMedGoogle Scholar
  • 8 Twilt M. et al. Long-term followup of temporomandibular joint involvement in juvenile idiopathic arthritis. Arthritis Rheum 2008; 59 (04) 546-552.
    CrossrefPubMedGoogle Scholar
  • 9 Hospach T. et al. Cervical spine involvement in patients with juvenile idiopathic arthritis - MRI follow-up study. Pediatr Rheumatol Online J 2014; 12: 9
    CrossrefPubMedGoogle Scholar
  • 10 Elhai M. et al. Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2013; 52 (02) 267-275.
    CrossrefPubMedGoogle Scholar
  • 11 Ringold S. et al. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009; 48 (08) 972-977.
    CrossrefPubMedGoogle Scholar
  • 12 Ansell BM. Juvenile chronic arthritis with persistently positive tests for rheumatoid factor (sero-positive juvenile rheumatoid arthritis). Ann Pediatr (Paris) 1983; 30 (08) 545-550.
    PubMedGoogle Scholar
  • 13 Schanberg LE. et al. Pain, stiffness, and fatigue in juvenile polyarticular arthritis: contemporaneous stressful events and mood as predictors. Arthritis Rheum 2005; 52 (04) 1196-1204.
    CrossrefPubMedGoogle Scholar
  • 14 Sabri K. et al. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS 2008; 12 (06) 539-545.
    CrossrefPubMedGoogle Scholar
  • 15 Kotaniemi K. et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 2001; 108 (11) 2071-2075.
    CrossrefPubMedGoogle Scholar
  • 16 Heiligenhaus A. et al. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 2013; 21 (03) 180-191.
    CrossrefPubMedGoogle Scholar
  • 17 Schmeling H. et al. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 2014; 66 (09) 2580-2589.
    CrossrefPubMedGoogle Scholar
  • 18 Hollenbach JA, Thompson SD, Bugawan TL. et al. Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. Arthritis Rheum 2010; 62: 1781-1791.
    CrossrefPubMedGoogle Scholar
  • 19 Hersh AO, Prahalad S. Immunogenetics of juvenile idiopathic arthritis: A comprehensive review. J Autoimmun 2015; 64: 113-124.
    CrossrefPubMedGoogle Scholar
  • 20 Dueckers G. et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012; 142 (02) 176-193.
    CrossrefPubMedGoogle Scholar
  • 21 Beukelman T. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63 (04) 465-482.
    CrossrefPubMedGoogle Scholar
  • 22 Niehues T. 2011 Leitlinien AWMF Register Nr. 027/020
  • 23 Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294 (13) 1671-1684.
    CrossrefPubMedGoogle Scholar
  • 24 Beukelman T. et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 2012; 39 (09) 1867-1874.
    CrossrefPubMedGoogle Scholar
  • 25 Giannini EH. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children‘s Study Group. N Engl J Med 1992; 326 (16) 1043-1049.
    CrossrefPubMedGoogle Scholar
  • 26 Alsufyani K. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004; 31 (01) 179-182.
    Google Scholar
  • 27 Ruperto N. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50 (07) 2191-2201.
    CrossrefPubMedGoogle Scholar
  • 28 Céspedes-Cruz A. et al. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 2008; 67 (03) 309-314.
    PubMedGoogle Scholar
  • 29 Albers HM. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 46-51.
    PubMedGoogle Scholar
  • 30 Savolainen HA. et al. Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol 1997; 24 (12) 2444-2450.
    Google Scholar
  • 31 Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 1986; 13: 118-123.
    Google Scholar
  • 32 Curtis JR. et al. Clinical Response within 12 Weeks as a Predictor of Future Low Disease Activity in Early RA Patients: Results from the TEAR Trial. J Rheumatol 2013; 40 (05) 572-578.
    CrossrefPubMedGoogle Scholar
  • 33 Hissink Muller. et al. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study. Pediatric Rheumatology 2017; 15: 11
    CrossrefPubMedGoogle Scholar
  • 34 Smolen JS. et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353 9149 259-266.
    CrossrefPubMedGoogle Scholar
  • 35 Silverman E. et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352 (16) 1655-1666.
    CrossrefPubMedGoogle Scholar
  • 36 Ringold S. et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2014; 66: 1063-1072.
    CrossrefPubMedGoogle Scholar
  • 37 Breit W. et al. A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 2000; 27 (11) 2696-2702.
    Google Scholar
  • 38 Huppertz HI. et al. Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past. Rheumatol Int 2011; 31 (10) 1259-1262.
    CrossrefPubMedGoogle Scholar
  • 39 Huppertz HI. Recommendations for juvenile idiopathic arthritis by the American College of Rheumatology: comment on the article by Beukelman. et al. Arthritis Care Res (Hoboken) 2011; 63 (09) 1354-1355. author reply 1355-1356
    CrossrefPubMedGoogle Scholar
  • 40 Huppertz HI, Lehmann HW. Evidence of treatment of chronic inflammation in childhood and adolescence with biologics. Z Rheumatol 2014; 73 (10) 907-916.
    CrossrefPubMedGoogle Scholar
  • 41 Beukelman T, Brunner H. Chapter 6 in: Petty R, Laxer R, et al. Textbook of Pediatric Rheumatology. Toronta, Canada: Elsevier; 2016
    Google Scholar
  • 42 Horneff G. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68 (04) 519-525.
    CrossrefPubMedGoogle Scholar
  • 43 Lovell DJ. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58 (05) 1496-1504.
    CrossrefPubMedGoogle Scholar
  • 44 Lovell DJ. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342 (11) 763-769.
    CrossrefPubMedGoogle Scholar
  • 45 Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 2011; 50 (01) 214-221.
    CrossrefPubMedGoogle Scholar
  • 46 Nielsen S. et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008; 26 (04) 688-692.
    PubMedGoogle Scholar
  • 47 Beukelman T. et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64: 2773-2780.
    CrossrefPubMedGoogle Scholar
  • 48 Toussi SS. et al. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013; 57 (09) 1318-1330.
    CrossrefPubMedGoogle Scholar
  • 49 McCroskery P. et al. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010; 8: 18-26.
    CrossrefPubMedGoogle Scholar
  • 50 Beukelman T. et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64 (04) 1263-1271.
    CrossrefPubMedGoogle Scholar
  • 51 Simard JF. et al. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010; 62 (12) 3776-3782.
    CrossrefPubMedGoogle Scholar
  • 52 Lovell DJ. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359 (08) 810-820.
    CrossrefPubMedGoogle Scholar
  • 53 Brunner H, Ruperto N, Tzaribachev N. et al. A 148: a multi-center, doubleblind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheum 2014; 66: S191-S192.
    CrossrefGoogle Scholar
  • 54 Ruperto N. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372 9636 383-391.
    CrossrefPubMedGoogle Scholar
  • 55 Brunner HI. et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74 (06) 1110-1117.
    CrossrefPubMedGoogle Scholar
  • 56 Holzinger D. et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2012; 71 (06) 974-980.
    CrossrefPubMedGoogle Scholar
  • 57 Arkela-Kautiainen et al. Favourable social functioning and health related quality of life of patients with JIA in early adulthood. Ann Rheum Dis 2005; 64: 875
    CrossrefPubMedGoogle Scholar
  • 58 Selvaag AM. et al. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis 2016; 75 (01) 190-195.
    CrossrefPubMedGoogle Scholar
  • 59 Swart JF, de Roock S, Wulffraat NM. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?. Arthritis Res Ther 2013; 15 (03) 213
    CrossrefPubMedGoogle Scholar
  • 60 Oen K, Malleson PN, Cabral DA. et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29 (09) 1989-1999.
    Google Scholar
  • 61 Minden K, Niewerth M, Listing J. et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46 (09) 2392-2401.
    CrossrefPubMedGoogle Scholar
  • 62 Foster HE, Marshall N. et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003; 48 (03) 767-775.
    CrossrefPubMedGoogle Scholar
  • 63 Flato B. et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003; 30 (02) 386-393.
    Google Scholar
  • 64 Lurati A. et al. Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases. J Rheumatol 2009; 36 (07) 1532-1535.
    CrossrefPubMedGoogle Scholar
  • 65 Nordal E, Zak M, Aalto K. et al. Nordic Study Group of Pediatric Rheumatology. Ongoing disease activity and changing categories in a long-term Nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 2809-2818.
    CrossrefPubMedGoogle Scholar